The Israeli generic pharma company is a huge beneficiary of the $150 billion in drug sales losing patent protection through 2014. As this happens, demand for cheaper medicines will skyrocket in emerging markets, says Leerink Swann analyst John Sullivan. China, Russia, and India spend less than 6% of GDP on health care, vs. 15% in the U.S.
